Navigation Links
Thomas Dietz, Ph.D., Elected Chairman of Galleon Pharmaceuticals
Date:10/26/2011

HORSHAM, Pa., Oct. 26, 2011 /PRNewswire/ -- Galleon Pharmaceuticals, a leader in the pharmaceutical treatment of breathing-control disorders, announced today that its board of directors has elected Thomas J. Dietz, Ph.D., as the company's chairman.  Dr. Dietz is chairman and CEO of Waypoint Holdings, LLC, a diversified financial-holdings and services company.  

Previously, Dr. Dietz was co-CEO and then CEO and a director of Pacific Growth Equities, LLC, a San Francisco-based investment bank and institutional brokerage firm from 2004 to 2009, when the firm was acquired by Wedbush Securities.  Dr. Dietz served as head of the investment banking division at Wedbush until November 2010.  

Prior to taking the CEO role at Pacific Growth, Dr. Dietz served as the company's director of equities research and was an award-winning biotechnology and biopharmaceutical analyst.  He joined Pacific Growth in 1993.  Previously, he was a member of the research faculty in the Department of Medicine, University of California, San Francisco and the VA Medical Center.  Dr. Dietz is a member of several national societies and currently serves on the boards of trustees of several non-profit organizations, including the West Bay Region board of the Sutter Health System that includes California Pacific Medical Center, San Francisco.  

Dr. Dietz holds a Ph.D. in molecular biology and biochemistry from Washington University, St. Louis, and was a National Science Foundation Post-Doctoral Fellow.  

About Galleon Pharmaceuticals

Galleon is the first pharmaceutical company to focus primarily on the drug treatment of breathing-control disorders.  Its initial goals are to improve the safety, efficacy and economics associated with the acute care of surgical patients and longer-term care of patients with conditions such as moderate-to-severe pain or sleep apnea.  In the United States alone, it is estimated that 100 million patients are at risk for a breathing-control disorder due to drugs, diseases or genetics.

The company's product pipeline reflects recent advances in neurobiology, molecular biology and respiratory medicine which have enabled the development of a unique drug-discovery platform and promising drug candidates that are now undergoing clinical trials.  Galleon's integrated discovery and development approach is unique among pharmaceutical companies and enables the rapid evaluation of multiple variables to establish a comprehensive profile of breathing-control activity.  For more information, please visit www.galleonpharma.com.  


'/>"/>
SOURCE Galleon Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Rib-X Pharmaceuticals, Inc. Co-Founder, Thomas A. Steitz, Ph.D., Awarded the 2009 Nobel Prize in Chemistry
2. Chimerix Appoints Thomas Pitler, Ph.D., Vice President, Business Development
3. K-V Pharmaceutical Names Thomas McHugh Chief Financial Officer
4. Accera, Inc. Appoints Dr. Thomas Werner President & CEO and Announces FDA Acceptance of IND Application for AC-1204 for Mild-to-Moderate Alzheimers Disease
5. Excaliard Pharmaceuticals Appoints Thomas Wiggans to Chairman of the Board
6. MAP Pharmaceuticals Appoints Thomas P. McCracken as Vice President, Intellectual Property
7. Osteotechs Plexur M® Technology Wins Thomas Alva Edison Patent Award from the New Jersey Research and Development Council
8. PharMEDium Hires Thomas W. Rasnic as Vice President, Quality, Regulatory Affairs and Research and Development
9. Symmetry Medical Board of Directors Appoints Thomas J. Sullivan President and Chief Executive Officer
10. Solta Medical, Inc. Appoints Thomas J. Yorkey, Ph.D. to Vice President of Research & Development
11. Thomas, McNerney & Partners Expands Team and Moves West Coast Office to San Diego
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , Oct. 12, 2017 AVACEN Medical ... the company with their  2017 New Product Innovation Award ... on extensive primary and secondary medical device market research by ... through its first-to-market OTC, drug-free pain relief product, the AVACEN ... approach to treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... 11, 2017  True Health, a leader in ... effort during National Breast Cancer Awareness month to ... Research recently ... that more than 10 million American women are ... BRCA1 or BRCA2 and have not had testing. These ...
(Date:10/5/2017)... Oct. 5, 2017  In response to the ... and Maxillofacial Surgeons (AAOMS) released prescribing recommendations that ... be used as a first-line therapy to manage ... Recognizing the value and ... Paper "Opioid Prescribing: Acute and Postoperative Pain Management" ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Dickinson ... offers insurance and financial preparation services, is providing an update on a charitable ... , Rock City Rescue is a locally recognized nonprofit that provides shelter and ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health ... technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing ... form that can be easily incorporated into liquid products, while reducing costs to end ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset ... of specialty vendors and unique items from across the nation, this holiday-themed event will ... services offered by the VNA. The boutique will be open Saturday, November 4 ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the ... today its plans to open a flagship location in Covington, LA at 401 N. ... To Go store next to Office Depot in the Holiday Square shopping center. Its ...
Breaking Medicine News(10 mins):